Vidya Mave, MD, MPH

Dr. Mave is Co-Director of the Center for Infectious Diseases in India and Associate Professor at the Johns Hopkins School of Medicine. She is also Director and Clinical Research Site (CRS) Leader of the Johns Hopkins University Baltimore-India Clinical Trials Unit (JHUBI-CTU) in Pune, India. The CTU is a collaborative research partnership between BJGMC in Pune, India and Johns Hopkins School of Medicine that is part of the world’s largest HIV therapeutic trial networks (the AIDS Clinical Trials Group [ACTG] and the International Maternal Pediatric and Adolescent AIDS Clinical Trial Network [IMPAACT]). 

Dr. Mave has more than 20 years of experience in clinical practice, education, and research in infectious diseases and has published more than 100 peer-reviewed research articles. Following a short tenure as Assistant Professor of Infectious Diseases at Tulane University School of Medicine, Dr. Mave joined the Johns Hopkins in 2010. She now leads and coordinates all clinical research activities for the JHUBI-CTU, which conducts phase I, II, and III clinical trials of therapeutic drug interventions for HIV and co-morbid infections, including TB and hepatitis, in adults (including pregnant women) and children. Dr. Mave’s research interests include TB clinical trials (of vaccines and new and re-purposed drugs) to optimize treatment outcomes; comorbidities (including diabetes, HIV), and the use of novel tools (Hair PK, whole genome sequencing, host biomarkers) to study TB treatment outcomes; and assessing best implementation strategies in programmatic settings. In addition, Dr. Mave has mentored more than 20 pre- and postdoctoral trainees from Johns Hopkins. 

Dr. Mave received an MD in medicine from Karnatak University, Dharwad, India, and an MPH from Tulane University. She completed her internal medicine training at St. Barnabas Hospital in New York, followed by a post-doctoral fellowship in infectious diseases at Tulane University and Long Island Jewish Medical Center. Dr. Mave is board certified in internal medicine and infectious diseases by the American Board of Internal Medicine. 

Leadership 

• Protocol Chair, A 5384: A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM) 

• Co-Vice Chair, ACTG Tuberculosis Transformative Science Group 

• Protocol Vice Chair, A5397/HVTN 603: A Phase 2A/2B Study Evaluating Safety and Immunogenicity of Therapeutic ID93 + GLA-SE Vaccination in Participants with Rifampicin-susceptible Pulmonary TB.